Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)
ID: 358910Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $330K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358910
Timeline
    Description

    The National Institutes of Health (NIH) is offering a Limited Competition Renewal for the continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required) under Funding Opportunity Number RFA-DK-26-308. This opportunity aims to complete enrollment in the Liver Cirrhosis Network Cohort and the Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU) clinical studies, specifically targeting current grant recipients of RFA-DK-20-003, with a limit of one application per institution. The initiative is crucial for advancing clinical and translational research on cirrhosis treatments and outcomes, with the NIH planning to commit approximately $3.3 million in FY 2026 for up to ten awards, each with a maximum project period of five years. Applications are due by March 6, 2026, and interested parties can contact the Division of Digestive Diseases and Nutrition at NIDDK_DDN@nih.gov for further information.

    Point(s) of Contact
    NIDDK_DDN@nih.gov
    Files
    Title
    Posted
    RFA-DK-26-308-Full-Announcement.html
    The Department of Health and Human Services is issuing a Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required) with Funding Opportunity Number RFA-DK-26-308. This renewal aims to complete enrollment in the Liver Cirrhosis Network Cohort and the Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU) clinical studies. Eligible applicants are current grant recipients of RFA-DK-20-003, with only one application allowed per institution. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to commit $3,300,000 in FY 2026 for up to ten awards, each with a maximum project period of five years. Applications must propose a clinical trial and are due by March 6, 2026, for renewal/resubmission/revision. The Liver Cirrhosis Network, a cooperative agreement, will involve Clinical Centers, a Scientific Data Coordination Center (renewing under RFA-DK-26-309), and NIH components, all governed by a Steering Committee. Applicants must address patient recruitment and retention, biospecimen collection, and include a Scientific Exploratory Specific Aim utilizing existing LCN data, without budgeting for its implementation in this application. The goal is to advance clinical and translational research on cirrhosis treatments and outcomes.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required). This initiative aims to solicit applications for research focused on liver cirrhosis, specifically to complete enrollment in ongoing studies, including the Liver Cirrhosis Network Longitudinal Cohort Study and the RESCU clinical trial. The program is significant for advancing understanding and treatment of liver diseases, with an estimated total funding of $3,302,147 and an award ceiling of $330,214, anticipating approximately 10 awards. Interested applicants, particularly small businesses with expertise in liver disease research, are encouraged to prepare for application submission, with the estimated synopsis post date on July 11, 2025, and a closing date of August 15, 2025. For further inquiries, contact Edward Doo, MD, at dooe@niddk.nih.gov or call 301-451-4524.
    Notice of Intent to Publish a Funding Opportunity Announcement for Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Liver Cirrhosis Network: Scientific and Data Coordination Center, aimed at soliciting applications for research on liver cirrhosis. This initiative seeks to complete enrollment in two ongoing studies: the Liver Cirrhosis Network Longitudinal Cohort Study and the RESCU clinical trial, which evaluates the efficacy and safety of rosuvastatin for cirrhosis. The selected cooperative agreement will provide essential clinical studies management and biostatistical assistance for data analyses and dissemination of findings. Interested small businesses are encouraged to prepare for application submission, with an estimated total program funding of $1,835,051 and a projected award date of July 1, 2026. For further inquiries, potential applicants may contact Dr. Edward Doo at dooe@niddk.nih.gov or by phone at 301-451-4524.
    Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Interventions to Address Disparities in Liver Diseases and Liver Cancer," aimed at supporting research interventions that target health disparities in liver diseases and liver cancer among marginalized populations in the United States. This initiative encourages researchers to propose multi-level and multi-domain approaches that address social determinants of health, with a focus on improving screening, treatment, and health outcomes for affected groups, including racial and ethnic minorities and individuals with lower socioeconomic status. The grant has no specific budget limit and allows for a maximum project period of five years, with applications accepted starting September 5, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address Disparities in Liver Diseases and Liver Cancer," aimed at supporting research initiatives that develop and test multi-level and multi-domain interventions to reduce health disparities related to liver diseases among marginalized populations in the United States. The initiative encourages applicants to design community-engaged and culturally sensitive approaches focusing on screening, prevention, treatment, and management of liver conditions, particularly targeting racial and ethnic minorities, individuals of low socioeconomic status, and those in underserved communities. This grant is crucial for addressing systemic issues that influence health access and outcomes, with applications due starting January 5, 2025, and a maximum project duration of five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Renewal of NIA Research Centers Collaborative Network (RCCN)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the renewal of the Research Centers Collaborative Network (RCCN), aimed at enhancing collaborations across its seven research centers focused on aging research. This initiative seeks to leverage NIH's significant investments by fostering interdisciplinary efforts and sustaining high-value activities, while also encouraging new initiatives such as pilot funding programs and enhanced mentoring infrastructure. Interested applicants, particularly those with expertise in aging research, are advised to prepare for this opportunity, with the estimated synopsis posting date on March 1, 2026, and a closing date for applications anticipated by May 25, 2026. For further inquiries, potential applicants can contact Amelia Karraker at amelia.karraker@nih.gov or by phone at 301-496-3131.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Silvio O. Conte Digestive Diseases Research Core Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) grant program, aimed at enhancing research collaboration in digestive and liver diseases. Eligible applicants must demonstrate a strong ongoing research base with at least $3 million in direct costs per year, including a minimum of 30% funding from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and must focus on a central theme relevant to the NIDDK's mission. This program is crucial for fostering productivity and innovation among researchers, with an expected four awards to be made, and applications are due by July 27, 2026. For further inquiries, interested parties can contact Dr. Katrina J. Serrano at katrina.serrano@nih.gov or by phone at 301-480-7855.
    Notice of Intent to Publish the re-issuance of the Notice of Funding Opportunity (NOFO) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) under the Rare Diseases Clinical Research Network (RDCRN), aimed at enhancing research in the diagnosis, management, and treatment of rare diseases. Each RDCRC is required to focus on at least three rare diseases and propose two to four clinical research projects, including one longitudinal study, emphasizing a collaborative, multi-site approach to address significant clinical trial readiness gaps. This initiative reflects the government's commitment to advancing public health through innovative methodologies and stakeholder engagement in the rare disease domain, with applications expected to be due in June and fall of 2025. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.